Author:
Sharan Mehak,Mathur Runjhun,Kumar Jha Niraj,Rana Khushboo,Kumar Jha Saurabh,Kumar Jha Abhimanyu
Abstract
It has been believed that identification of alterations in epigenetic profiles can be used to distinguish not only between various types of malignancies but also between different phases of cancer progression. As a result, epigenetic factors have a lot of potential to become more accurate diagnostic and prognostic biomarkers for many malignancies. Although DNA methylation is the most researched aspect of epigenetics, only a few methylation markers are routinely used in clinical practice. DNA methylation biomarkers, on the other hand, are expected to play a significant role in the near future. To summarize, epigenetic regulation plays a critical role in cancer development, and epigenetic biomarker analysis has a lot of potential to become clinically useful. More research is needed to further develop and evaluate epigenetic biomarkers\' therapeutic use.
Reference109 articles.
1. Hajdu SI. A note from history: Landmarks in history of cancer, part 1. Cancer. 2011;117(5):1097-1102
2. Paul of Aegina, 7th Century AD, quoted in Moss, Ralph W. “Galen on Cancer.” Cancer Decisions. Archived from the original on 16 July 2011. Referenced from Michael Shimkin, Contrary to Nature, Washington, DC: Superintendent of Document, DHEW Publication No. (NIH). 2004. 79–720, p. 35
3. Hajdu SI. A note from history: Landmarks in history of cancer, part 2. Cancer. 2011;117(12):2811-2820
4. Yalom M. A History of the Breast. 1st ed. New York: Ballantine Books; 1998
5. “Cancer”. World Health Organization. 12 September 2018. Retrieved 19 December 2018